Andexanet Alfa: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
SMC (Scotland) recommended or restricted andexanet alfa, while AIFA (Italy), CIPM (Spain) and DMC (Denmark) did not recommend it.
Assessment has run over 6.6 years, from 6 Jun 2019 at AWMSG (Wales) to 22 Jan 2026 at G-BA (Germany).
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for andexanet alfa, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 11 records date from 2023 or later.
Against its own class, andexanet alfa is an outlier: 20% of its decisive outcomes were positive, where molecules sharing ATC class V03A average 77%.
4 distinct indication wordings are recorded for andexanet alfa by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess andexanet alfa, on 6 Jun 2019; G-BA (Germany) did not open a file until 22 Jan 2026 — a wide spread of 6.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 6 years in total.
2 of the 9 agencies here assessed andexanet alfa more than once, NICE (England) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for andexanet alfa.
The full ledger for andexanet alfa reads 4 not recommended, 2 terminated, 1 no benefit and 1 other, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 16 Mar 2025 | Til voksne som behandles med en direkte faktor Xa (FXa)-hemmer (apiksaban eller rivaroksaban) når det er behov for rever… | decision recorded | source |
| NICE (England) | 15 Jan 2025 | NICE TA1029 | terminated appraisal | source |
| CHUIKYO (Japan) | 18 May 2022 | オンデキサ: cost-effectiveness evaluation (high budget impact) | evaluation completed, price adjustment decided | source |
| AIFA (Italy) | 22 Mar 2022 | ONDEXXYA è indicato per pazienti adulti trattati con un inibitore diretto del fattore Xa (FXa) (apixaban o rivaroxaban),… | not reimbursed (class C) | source |
| CIPM (Spain) | 3 Mar 2022 | Indicaciones terapéuticas: Para pacientes adultos tratados con un inhibidor directo del factor Xa (apixabán o rivaroxabá… | not financed by the SNS · art. 92 c, d | source |
6 further decisions for andexanet alfa, across 6 agencies, are not shown here. They include the most recent record on file, 22 Jan 2026 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- sevelamer — same ATC class V03A — Other therapeutic products
- deferasirox — same ATC class V03A — Other therapeutic products
- patiromer — same ATC class V03A — Other therapeutic products
- deferiprone — same ATC class V03A — Other therapeutic products
- difelikefalin — same ATC class V03A — Other therapeutic products
- naloxone — same ATC class V03A — Other therapeutic products
Coverage: 11 decisions for andexanet alfa from 9 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class V03A — Other therapeutic products. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.